This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on July 8, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

GMP Grade Human Interleukin-2 (IL-2) from ACROBiosystems Inc.

Closed

26-006951Federal

Submission Closed07/17/2026, 11:00:00 AM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414

New

SLED

Life Science Reagent and Assay SupplyThe contract pertains to the supply of proprietary molecular biology reagents, diagnostic kits, and assay components including PCR kits and nucleic acid purification systems intended for use in research or clinical environments. These materials are critical for laboratories conducting genetic analysis, pathogen detection, and other molecular diagnostics, requiring high purity, consistency, and regulatory compliance. The contract is classified as a subcontract under NAICS code 325414, indicating it involves the manufacturing of biochemical and biophysical substances, and is issued by the state of Utah with a posted date of July 27, 2026, and a response deadline of August 3, 2026. There is no specified set-aside status or point of contact provided, and the place of performance details are incomplete, though the sourcing and delivery are expected to support internal operations or downstream clients of the procuring entity.

POSTED

DEADLINE

Manufacturer of Assayed Human Serum ControlsThe contract requires the manufacture of liquid human serum-based, level 3 assayed controls containing over 50 analytes for use in clinical chemistry testing, with strict adherence to FDA compliance standards and certified assay accuracy to ensure reliable diagnostic performance. The controls must meet rigorous quality benchmarks to support clinical laboratories in maintaining precision and traceability across a broad spectrum of biochemical parameters. The solicitation is issued under the Department of Defense’s Medical Supply Chain MD Surg FSF as a subcontract, with a response deadline of August 3, 2026, and a place of performance designated as APO 09227-0000. The North American Industry Classification System code 325414 identifies the work as falling under pharmaceutical and medicinal chemical manufacturing, emphasizing the need for specialized expertise in biological product formulation. All deliverables must be fully compliant with regulatory requirements, and the manufacturer is expected to demonstrate proven capability in producing high-integrity analytical controls under controlled conditions.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Condom Supply and PackagingThe contract requires the supply of FDA-compliant lubricated latex condoms containing Nonoxynol-9, packaged in standardized formats of three per strip and 1008 per bulk unit, adhering to both hazardous material handling guidelines and military packaging specifications. All products must meet stringent regulatory and safety standards to ensure reliability and compliance during storage, transport, and use in military or federal medical environments. The items are intended for distribution through established defense supply chains and must be manufactured and packed to withstand rigorous conditions without compromise to integrity or function. Submission deadlines for proposals are set for August 3, 2026, with the solicitation issued under the NAICS code 325414 for contraceptive manufacturing. The contracting activity originates from the Department of Defense through the Medical Supply Chain MD Surg FSF, with performance and delivery expected to occur at the specified location in Annville, Pennsylvania, 17003-5003. This subcontract opportunity is open to qualified vendors capable of meeting exacting packaging and compliance thresholds, and all bids must be submitted through the designated DIBBS platform prior to the closing date.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Medical Diagnostic Test Kit Manufacturing and PackagingThe contract pertains to the manufacture and packaging of qualitative hCG pregnancy test kits designed to meet stringent diagnostic standards, including specific sensitivity thresholds, minimum shelf-life requirements, and full compliance with labeling regulations. All components must be sourced, assembled, and packaged to ensure consistent performance and regulatory adherence, with strict quality control protocols applied throughout production. The work is to be performed at Fort Bragg, North Carolina, under a subcontract arrangement within the Department of Defense’s Medical Supply Chain network, and all deliverables must align with the technical specifications and compliance expectations set forth by the contracting entity. Bids must be submitted by August 3, 2026, and the NAICS code 325414 indicates this falls under the medical and dental instrument manufacturing sector. The contract is part of a broader effort to ensure reliable, on-demand diagnostic capacity for military and related healthcare operations. While no set-aside status is specified, the project requires full adherence to federal procurement standards for medical devices, including documentation of batch traceability, environmental controls during packaging, and validation testing to confirm accuracy and uniformity across production runs. The kits will be deployed in field medical settings, necessitating durability, clear labeling, and compatibility with existing clinical workflows.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Medical Device Manufacturing – Nonabsorbable SuturesThe contract concerns the manufacture of sterile, nonabsorbable polypropylene sutures identified by NSN 6515-01-153-4753, specified as size 4-0, blue, 18-inch, and single-armed, adhering strictly to medical device standards and detailed contract specifications. The product must meet rigorous quality and performance benchmarks appropriate for surgical use, ensuring sterility, consistency, and reliability under clinical conditions. Production and compliance verification are expected to align with applicable regulatory frameworks governing medical devices. This is a subcontract opportunity posted by the Department of Defense under the Medical Supply Chain MD Surg FSF, with performance required at a location in Groton, Connecticut, ZIP code 06340-4905. The solicitation was posted on July 26, 2026, with a firm deadline for responses on August 3, 2026. The NAICS code 325414 identifies the industry classification as medical and surgical instrument manufacturing, indicating the technical scope and regulatory expectations for the supplier. Interested parties must respond through the designated DIBBS portal before the deadline to be considered for award.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Supplier of Intravenous Administration Sets (Selectable Drip)The contract is for the supply of intravenous administration sets featuring selectable drip capabilities, as detailed in CLINs 0001 through 0005, and must strictly comply with Department of Defense technical specifications. This subcontract is issued under NAICS code 325414 by the Medical Supply Chain MD Surg FSF, a division of the Department of Defense, with performance required at the facility located in Waco, Texas, zip code 76707-1019. All delivered products must meet defined regulatory and functional standards to ensure compatibility and safety in clinical use. The solicitation was posted on July 26, 2026, with responses due by August 3, 2026, and bidders are expected to demonstrate compliance with quality, packaging, labeling, and delivery requirements as stipulated by the agency’s procurement guidelines.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Medical Supply Packaging and LabelingThe contract entails the packaging and labeling of intravenous administration sets and other medical supplies in strict adherence to federal standards, including ASTM D3951 for packaging and DLA marking requirements for uniform identification and traceability. All work must ensure that products meet rigorous defense and medical logistics specifications to maintain compatibility with military supply chains and operational readiness. The performance location is designated as Waco, Texas, with a zip code of 76707-1019, and the work falls under NAICS code 325414, which classifies it under pharmaceutical and medical preparation manufacturing. This is a subcontract opportunity issued by the Department of Defense under the Medical Supply Chain MD Surg FSF, with proposals required by August 3, 2026. The solicitation is part of an ongoing effort to secure reliable and compliant packaging solutions for critical medical items used by military and healthcare providers. The contract demands precise adherence to labeling and packaging protocols to ensure seamless integration into federal inventory systems and field deployment systems, with no tolerance for noncompliance that could disrupt distribution, inventory control, or patient safety. Participation requires demonstrated experience with DLA standards and the ability to meet strict federal quality and documentation controls.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Production of 4,000 Final Lateral Flow StripsThe contract requires the manufacture of 4,000 final lateral flow strips for pre-clinical testing, strictly adhering to a validated design and specifications set by the Centers for Disease Control and Prevention. The work must be performed in compliance with all technical and quality requirements established by the CDC to ensure the strips are suitable for intended pre-clinical use. The project is classified as a subcontract under NAICS code 325414, which corresponds to pharmaceutical and biological product manufacturing, indicating the need for specialized expertise in diagnostic device production. The place of performance is designated as Atlanta, Georgia, with the final deliverables expected to meet CDC’s rigorous standards for accuracy, consistency, and functionality. The solicitation was posted on July 24, 2026, with a response deadline of July 29, 2026, at 7:00 PM Eastern Time, leaving a limited window for qualified vendors to submit proposals. The contracting agency is the CDC Office of Acquisition Services under the Department of Health and Human Services, underscoring the public health significance of the project. While no set-aside provisions or specific organization type requirements are noted, bidders must be prepared to demonstrate capacity, regulatory knowledge, and quality control processes capable of delivering precisely specified diagnostic strips under a tight timeframe. The opportunity is accessible through the SAM.gov platform, and full compliance with CDC guidelines is non-negotiable for contract award.

CDC Office Of Acquisition Services

POSTED

DEADLINE

Supply of Unspecified Pharmaceutical or Medical Item (CLIN 0001)The contract requires the delivery of a boxed medical item, potentially a medical kit or device, with strict adherence to proper packaging, labeling, and all applicable regulatory standards to ensure safety and compliance. The item is subject to procurement under NAICS code 325414, which pertains to pharmaceutical and biological product manufacturing, indicating the product's classification as a pharmaceutical or medical supply. Performance is mandated at Fort Bragg, North Carolina, with a delivery deadline of July 29, 2026, and the solicitation was posted on July 23, 2026, allowing a six-day window for responses. This is a subcontract under the Department of Defense’s Medical Supply Chain PHARM FSA, suggesting integration into a larger military medical logistics framework. All units must meet federal and defense-specific requirements for handling, documentation, and distribution within the U.S. military healthcare system.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Manufacture of Sterile Petrolatum Gauze DressingsThe contract calls for the full-scale production of sterile, adhesive petrolatum-impregnated gauze dressings, encompassing every stage from raw material procurement through impregnation, sterilization, and rigorous quality testing to meet medical-grade compliance standards. All manufacturing processes must ensure consistent product integrity, sterility, and adherence to regulatory requirements for use in clinical and surgical environments. The work requires specialized capabilities in handling medical-grade materials, controlled impregnation techniques, and validated sterilization methods to guarantee safety and performance. Production is to be performed at the designated place of performance in Fort Hood, Texas, with a response deadline of July 29, 2026, and the solicitation was posted on July 23, 2026. The contract is classified as a subcontract under the NAICS code 325414, associated with the Department of Defense’s Medical Supply Chain, specifically the MD Surg FSF organization. The procurement is part of a broader effort to maintain reliable access to essential sterile wound care products for military medical operations, with an emphasis on supply chain resilience and quality assurance throughout the manufacturing lifecycle.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Supply of Blood Chemistry Control KitsThe contract requires the manufacture and supply of liquid general chemistry and lipid control combo kits designed specifically for use with Piccolo Express analyzers, with both high and low control levels provided in 1 mL vials, packaged in sets of twelve. These kits must be stored under frozen conditions to maintain stability and efficacy, and all labeling must meet strict regulatory compliance standards to ensure proper identification, handling, and traceability. The product is intended for medical diagnostic use within military healthcare settings and must adhere to precise technical and packaging specifications to guarantee performance consistency. The solicitation is issued under the Department of Defense through the Medical Supply Chain MD Surg FSF, with performance required at Camp Pendleton, California, zip code 92055-5627. It is categorized as a subcontract under NAICS code 325414 for pharmaceutical and medicinal preparation manufacturing, and responses are due by July 29, 2026, with the posting date set for July 23, 2026. The procurement is aimed at securing reliable, high-quality control materials to support clinical testing accuracy across military medical facilities, and suppliers must be prepared to meet all logistical, labeling, and storage requirements outlined in the solicitation.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Manufacture of Nonadherent Wound Dressing PadsThe contract requires the manufacture of medical-grade nonadherent wound dressing pads featuring a rayon/acrylic filler core, covered with a perforated transparent film for visibility and breathability, and individually sealed to maintain sterility. Each package must contain exactly 100 pads per envelope, adhering strictly to government standards for shelf life, labeling, and packaging integrity. The product must comply with all applicable regulatory requirements for medical devices intended for military and federal healthcare use, including proper identification, expiration dating, and traceability markings. Performance is expected to be delivered to a designated location in San Diego, California, with a response deadline set for July 29, 2026. This is a subcontract opportunity under the NAICS code 325414 for medical and surgical manufacturing, issued by the Department of Defense through the Medical Supply Chain MD Surg FSF. The solicitation is open to qualified suppliers capable of meeting stringent quality and compliance benchmarks for use in military medical operations.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

5 days ago

DEADLINE

in 1 day

AI Contract Overview

The National Institutes of Health, through its Clinical Center, intends to award a sole source firm-fixed-price purchase order to ACROBiosystems Inc. for fifteen vials of CytoPak GMP Human Interleukin-2 Protein, a critical biological component used in FDA-regulated cell and gene therapy manufacturing. The product is essential for ongoing clinical trials conducted by the Center for Cellular Engineering, where process validation and material consistency are mandatory to ensure patient safety and treatment efficacy. Substituting an alternative supplier would necessitate full revalidation of the manufacturing process, leading to significant delays, increased costs, and potential中断 of patient treatments that could result in eligibility loss for clinical trials. ACROBiosystems Inc. is the only known source capable of providing the validated formulation required by NIH’s approved protocols, justifying the use of a sole source procurement under FAR 13.106-1(b)(1). This acquisition falls under the category of Drugs and Biologicals with a NAICS code of 325414 and will be delivered to the NIH Clinical Center in Bethesda, Maryland. While this notice does not constitute a solicitation, interested parties may submit capability statements demonstrating their ability to meet the requirement by July 17, 2026, at 7:00 a.m. Eastern Time. The Government retains full discretion to accept or decline submissions and will not open the procurement to competition unless a capable alternative is identified that can match the existing validated product’s requirements without disrupting clinical operations.

General Info

NIH sole-source buys 15 vials of validated IL-2 from ACROBiosystems for critical cell therapy trials.

Agency

Department Of Health And Human Services → National Institutes Of Health OlaoView Agency

NAICS

325414 - Biological Product (except Diagnostic) ManufacturingView NAICS

Place of Performance

Bethesda, MD, 20892, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed

PostedJul 8

Presolicitation

Response DeadlineJul 17

Deadline has passed

Submission Closed

07/17/2026, 11:00:00 AM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao

Contacts1 person available

OfficeBETHESDA, MD, 20892, USA

Organization / Agency

Department Of Health And Human Services → National Institutes Of Health Olao

View Agency Profile

Office AddressBETHESDA, MD, 20892, USA

Contacts

Shasheshe Goolsby

contact@example.gov

+1 (555) 000-0000

Full Description

NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT

Title: GMP Grade Human Interleukin-2 (IL-2) from ACROBiosystems Inc.
Notice ID (POTS): 26-006951
Product Service Code (PSC): 6505 – Drugs and Biologicals
NAICS Code: 325414 – Biological Product (except Diagnostic) Manufacturing
Place of Performance: National Institutes of Health
Clinical Center
Bethesda, MD 20892

Description

This Notice of Intent (NOI) is issued for informational purposes only and does not constitute a Request for Quotations (RFQ). The Government does not intend to solicit competitive quotations for this requirement.

The National Institutes of Health (NIH), Clinical Center, Office of Acquisitions and Logistics Management (OALM), intends to award a sole source, firm-fixed-price purchase order to ACROBiosystems Inc., 1 Innovation Way, Suite 302, Newark, DE 19711, for the procurement of fifteen (15) vials of CytoPak GMP Human IL-2 Protein (Part Number: GMP-L02H14GB01), including shipping. The supplies support FDA-regulated cell and gene therapy manufacturing activities performed by the Center for Cellular Engineering (CCE).

Background

The Center for Cellular Engineering manufactures cell and gene therapies for NIH clinical trials. These FDA-regulated manufacturing processes require all components and materials to be validated to ensure product safety, quality, and consistency. The CytoPak GMP Human IL-2 Protein manufactured by ACROBiosystems has been validated for use in CCE's approved manufacturing processes. Substituting another manufacturer's product would require extensive process revalidation, resulting in significant cost and schedule impacts. During revalidation, patient treatment could be delayed, potentially causing disease progression that renders patients ineligible for clinical trials. Consequently, delaying this procurement would not be in the best interest of either the Government or the patients.

Sole Source Rationale

ACROBiosystems Inc. is the only known source capable of providing the validated CytoPak GMP Human IL-2 Protein required for NIH's approved manufacturing protocols. An alternate product would require complete manufacturing process revalidation, causing significant delays, increased costs, and interruption of patient treatment.

Authority

This acquisition is being conducted in accordance with FAR 13.106-1(b)(1), Soliciting from a Single Source. Under this authority, the Contracting Officer may solicit from a single source when only one source is reasonably available to satisfy the Government's requirements. Acquisitions conducted under FAR Part 13 are exempt from the competition requirements of FAR Part 6.

Responses

This is not a Request for Quotations. Interested parties may submit a capability statement demonstrating their ability to satisfy the Government's requirement. Responses should include:

• Company name and address
• Technical capability
• Proof of OEM authorization, if applicable
• Relevant past performance

The Government will evaluate all capability statements received. However, the determination not to compete this requirement remains solely within the Government's discretion.

Submission Instructions

Capability statements shall reference POTS 26-006951 and must be submitted electronically no later than July 17, 2026, at 7:00 a.m. Eastern Time (ET).

Shasheshe Goolsby
Team Leader
Hospital and Laboratory Support Division
Office of Acquisitions and Logistics Management
National Institutes of Health
Email: shasheshe.goolsby@nih.gov